CCA
GSK icon

Cravens & Co Advisors’s GSK GSK Stock Holding History

Cravens & Co Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$428K Buy
7,751
+184
+2% +$9.97K 0.28% 48
2025
Q4 		$378K Sell
7,567
-189
-2% -$8.81K 0.25% 48
2025
Q3 		$335K Sell
7,756
-3
-0% -$117 0.23% 47
2025
Q2 		$298K Buy
7,759
+170
+2% +$6.5K 0.22% 47
2025
Q1 		$294K Buy
+7,589
New +$278K 0.23% 48
2024
Q4 		– Sell
-7,459
Closed -$305K – 65
2024
Q3 		$305K Sell
7,459
-881
-11% -$36K 0.24% 51
2024
Q2 		$321K Sell
8,340
-197
-2% -$8.29K 0.24% 57
2024
Q1 		$366K Sell
8,537
-382
-4% -$15.8K 0.3% 54
2023
Q4 		$331K Sell
8,919
-315
-3% -$11.3K 0.29% 58
2023
Q3 		$335K Sell
9,234
-99
-1% -$3.51K 0.31% 58
2023
Q2 		$333K Sell
9,333
-76
-0.8% -$2.73K 0.31% 56
2023
Q1 		$335K Buy
9,409
+3
+0% +$105 0.31% 55
2022
Q4 		$331K Buy
+9,406
New +$313K 0.31% 59

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Cravens & Co Advisors's GSK Position: Q1 2026 in Review

Cravens & Co Advisors increased its GSK (GSK) stake by 2.4% in Q1 2026, buying an estimated $9.97K and bringing the position to 7,751 shares worth $428K. The position accounts for 0.28% of the portfolio, ranked #48.

Cravens & Co Advisors first reported a position in GSK in Q4 2022 and has held it in 13 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Cravens & Co Advisors held 7,751 shares of GSK worth $428K as of Q1 2026.
  • Cravens & Co Advisors bought 184 GSK shares in Q1 2026, an estimated $9.97K.
  • GSK made up 0.28% of Cravens & Co Advisors's portfolio in Q1 2026, its #48 holding.
  • Cravens & Co Advisors first reported a position in GSK in Q4 2022 and has held it in 13 quarters since.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Cravens & Co Advisors's 13F filing for Q1 2026, filed 14 May 2026.